Humacyte, Inc. (HUMA), a commercial-stage biotechnology platform developing implantable, bioengineered human tissue, is expected to present top-line interim results of its Phase 3 trial dubbed VO12, evaluating Acellular tissue-engineered vessel or ATEV in hemodialysis access on June 11, 2026, at the Society of Vascular Surgery's (SVS) Vascular Annual Meeting (VAM) in Boston.
ATEV (Acellular Tissue Engineered Vessel) is an investigational bioengineered human blood vessel designed as an implantable vascular conduit and is being evaluated as a potential alternative to traditional autogenous arteriovenous fistula (AVF).
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.